SCHEMBL2008333

SCHEMBL2008333

c1ccc2c(c1)COc1ccccc1N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.54
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 3/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
RAB9A P51151 2/20 0.42
AHR P35869 1/20 0.42
PDK2 Q15119 1/20 0.42
HSP90AA1 P07900 1/20 0.42
THRB P10828 1/20 0.42
HK1 P19367 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
GALK1 P51570 1/20 0.42
BLM P54132 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
MAPK13 O15264 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809130 0.82 NOX1 (0.42) ALOX5KMT2AHTR5A
SCHEMBL29485911 0.82 CMA1 (0.44) ALOX5GAAKMT2AMAPTKDM4E
SCHEMBL4811917 0.82 CMA1 (0.44) ALOX5GAAKMT2AMAPTKDM4E
SCHEMBL4807696 0.82 AHR (0.44) ALOX5GAAKMT2ANPC1MAPT
SCHEMBL4810558 0.82 ALOX5 (0.41) ALOX5GAAKMT2AMAPTKDM4E
SCHEMBL11442210 0.82 ALOX5 (0.48) ALOX5GAANPSR1KMT2ANPC1
SCHEMBL4809989 0.80 NR3C2 (0.47)
SCHEMBL14279325 0.80 AHR (0.41) ALOX5GAAKMT2ANPC1MAPT
SCHEMBL18173701 0.80 MMP12 (0.61) GAAKMT2ANPC1MAPTKDM4E
SCHEMBL4806003 0.80 NR3C2 (0.44) ALOX5GAAKMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1475373-A1 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists Ajinomoto Co., Inc. (JP) 2004-11-10 EP claimed
EP-1471060-A1 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists Ajinomoto Co., Inc. (JP) 2004-10-27 EP claimed
US-6528504-B2 Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. AJINOMOTO CO., INC. (JP) 2003-03-04 US claimed
EP-1020466-B1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME AJINOMOTO KK (JP) 2003-02-19 EP claimed
US-20020133004-A1 Process for producing new oxazepine derivatives AJINOMOTO CO. INC (JP) 2002-09-19 US claimed
US-6436922-B1 TREATING IRRITABLE BOWEL SYNDROME AJINOMOTO CO., INC. (JP) 2002-08-20 US claimed
US-20020099047-A1 Oxazepine derivatives and medicine containing the same AJINOMOTO CO., INC. (JP) 2002-07-25 US claimed
EP-1219611-A1 NOVEL PROCESSES FOR PREPARING OXAZEPINE DERIVATIVES Ajinomoto Co., Inc. (JP) 2002-07-03 EP claimed
EP-1142884-A1 OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2001-10-10 EP claimed
EP-0889043-B1 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE DERIVATIVES AND DRUG COMPOSITIONS CONTAING THE DERIVATIVES AJINOMOTO KK (JP) 2001-08-29 EP claimed
US-6127361-A FOR TREATMENT OR PREVENTION OF GASTROINTESTINAL MOVING FUNCTION DISORDERS, IRRITABLE BOWEL SYNDROME AJINOMO CO., INC. (JP) 2000-10-03 US claimed
EP-1020466-A1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2000-07-19 EP claimed
EP-0889043-A1 5,11-DIHYDRODIBENZ b,e] 1,4]OXAZEPINE DERIVATIVES AND DRUG COMPOSITIONS CONTAING THE DERIVATIVES Ajinomoto Co., Inc. (JP) 1999-01-07 EP claimed
US-12152216-B2 Benzazepine compounds as antioxidants for lubricant compositions The Lubrizol Corp tion (US) 2024-11-26 US disclosed
CN-115536585-B Iminostilbene derivative and preparation method thereof 中国医学科学院药用植物研究所 2024-04-30 CN disclosed
US-20240052256-A1 BENZAZEPINE COMPOUNDS AS ANTIOXIDANTS FOR LUBRICANT COMPOSITIONS THE LUBRIZOL CORPORATION 2024-02-15 US disclosed
EP-0613472-A1 10-ACYL-DIBENZ(B,F) (1,4)-OXAZEPINES AND THEIR THIAZEPINES ANALO GUES USEFUL AS PROSTAGLANDIN ANTAGONISTS G.D. SEARLE & CO. (US) 1994-09-07 EP disclosed
EP-0607864-A2 Tricyclic condensed heterocyclic compounds for the treatment of senile dementic Takeda Chemical Industries, Ltd. (JP) 1994-07-27 EP disclosed
US-4229350-A LOCAL ANESTHETICS, TREATMENT OF PARKINSON SYNDROME EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1980-10-21 US disclosed
US-4208410-A LOCAL ANESTHETICS, ANTIPARKINSON AGENTS EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1980-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099047-A1 Oxazepine derivatives and medicine containing the same CACNG5, GRIK5, KCNB1 ALOX5 138/4885GAA 2017/4885NPSR1 910/4885
US-20020133004-A1 Process for producing new oxazepine derivatives KMO, CYP4B1, GRIN2B ALOX5 235/4885GAA 2540/4885NPSR1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.